{"transactions":[{"id":2845538,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":142408,"kind":"person","name":"Seiter Christopher","position":1,"cik":"0001774627","reported_name":"Seiter Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-19T21:15:42.000Z","date":"2021-02-17","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 17, 2021. The 80,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 17, 2022 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 17, 2025."}],"balance_after":80000,"derivative":{"exercise_price":3.21,"expiration_date":"2031-02-16","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0000899243-21-007378","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000089924321007378/doc4.xml","form_type":"4"}},{"id":3266115,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":142408,"kind":"person","name":"Seiter Christopher","position":1,"cik":"0001774627","reported_name":"Seiter Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-02-18T21:15:52.000Z","date":"2020-02-13","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 13, 2020. The 65,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 13, 2021 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 13, 2024."}],"balance_after":65000,"derivative":{"exercise_price":5.5,"expiration_date":"2030-02-12","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0000899243-20-004872","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000089924320004872/doc4.xml","form_type":"4"}},{"id":3500007,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":142408,"kind":"person","name":"Seiter Christopher","position":1,"cik":"0001774627","reported_name":"Seiter Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2019-06-05T21:11:04.000Z","date":"2019-06-03","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 3, 2019. The 50,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on June 3, 2020 and as to the remaining 75% of the shares in equal monthly installments thereafter through June 3, 2023."}],"balance_after":50000,"derivative":{"exercise_price":10.12,"expiration_date":"2029-06-02","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-19-015609","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000089924319015609/doc4.xml","form_type":"4"}}]}